Thoracic Malignancies

ASCO Journal Club

Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology

Questions discussed in this category

Due to the high incidence of hyperlipidemia secondary to lorlatinib, do you recommend empiric statin therapy to all patients without known contraindications upon initiation of lorlatinib?

2 Answers available

Is there any role for ctDNA testing after surgery or SBRT for Stage IB NSCLC to determine the need for adjuvant chemotherapy?

1 Answer available

What do you view as the role for docetaxel+ramucirumab for patients with metastatic NSCLC in light of LUNG-MAP S1800A data?

Would you still use ram/doce in 3rd or later lines after ram/pembro?

3 Answers available

Are there differences in efficacy of ramucirumab + pembrolizumab based on extent and duration of response to first line chemo/pembro?

Did S1800a stratify by prior treatment response? Would you choose different 2L treatment for a patient who progresses rapidlly on pembro + platinum do...

3 Answers available

Are there any unique toxicity concerns with combination of ramucirumab/pembrolizumab as compared with other available treatments for metastatic NSCLC?

How do you counsel patients on the available second line options?

2 Answers available

Is there a role in sending liquid biopsy for patients progressing on ALK inhibitors?

1 Answer available

In patients with T790M mutation and progression of disease on osimertinib, is there any utility in checking peripheral blood cDNA for continued presence or absence of the T790M mutation?

1 Answer available

How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?

2 Answers available

Can ctDNA be used to evaluate response to checkpoint inhibitors in NSCLC when pseudoprogression is suspected on CT imaging?

1 Answer available

Papers discussed in this category

JCO Precision Oncology, 2017 Sep 29

Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician

Sci Rep, 2014 Sep 09

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.

Medicine (Baltimore),

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Oncotarget,

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.

Nature, 2017-04-26

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Cancer discovery, 2017-12

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Cancer discovery, 2016-10

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Lung cancer (Amsterdam, Netherlands), 2017-10

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

J Thorac Oncol, 2017 Oct 31

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.

Lancet (London, England), 2014-08-23

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Lancet (London, England), 2019-05-04

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

J Clin Oncol, 2022 Jun 03

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.

Thoracic Malignancies

ASCO Journal Club

Questions discussed in this category

Papers discussed in this category

Related Topics in Thoracic Malignancies